Dr. Law Weng Giap

Dr Law Weng Giap is a Rheumatologist with special interest in diagnostic and interventional musculoskeletal ultrasound. He has in excess of 20 years’ experience in managing various complicated autoimmune diseases including Systemic Lupus Erythematosus (SLE), Systemic Sclerosis, Myositis and various forms inflammatory arthritis such as Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Gout etc.

Dr Law graduated from the University of Sydney in 1995 with M.B.B.S (Honours). He obtained his postgraduate qualification MRCP (UK) in 2000. Dr Law subsequently underwent specialty training in Rheumatology at Tan Tock Seng Hospital. He is a Fellow of Academy of Medicine Singapore, Fellow of Royal College of Physicians of Edinburgh and International Fellow of American College of Rheumatology.

Prior to private practice, Dr Law was a Senior Consultant from Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital (TTSH). Apart from clinical practices, Dr Law was actively involved in teaching undergraduate medical students from Yong Loo Lin and Lee Kong Chian (LKC) Medical Schools, as well as teaching postgraduate Rheumatology trainees. He was appointed Adjunct Associate Professor with LKC School of Medicine and was also the Chairman of the Clinical Competency Committee, National Healthcare Group Rheumatology Residency Programme for TTSH. Dr Law’s interest in clinical research is clearly reflected in him being the site Principal Investigator and Collaborator of a several clinical trials in Systemic Sclerosis and Psoriatic Arthritis respectively. He was also the Quality Review Officer for his Department.

Dr Law aspires to prevent irreversible damage and reduce morbidity from autoimmune rheumatic diseases and inflammatory arthritis. With that, he strongly believes in the importance of early diagnosis and early aggressive treatment of these conditions.

Almost all Inflammatory Arthritides need treatment with Disease Modifying Anti-Rheumatic Drugs (DMARDs). Whereas most systemic autoimmune diseases such as SLE, scleroderma, myositis, MCTD etc need immunosuppressive therapy.

In very active arthritis and systemic autoimmune diseases, newer treatments with biologic or small molecule therapy such as anti- TNF, anti CD-20, anti-IL6, anti-IL17, Jak-inhibitors can prevent erosions in inflammatory arthritis and organ failure in various systemic autoimmune diseases.

1. Acute Lupus Myocarditis: Clinical features and outcome of an oriental case series. WG Law, BY Thong, TY Lian, KO Kong and HH Chng LUPUS: 2005; 14(10): 827-31
2. Acute Pan-dysautonomia: a rare initial presentation of lupus with Sjogren’s Syndrome. WG Law. BY Thong, Umapathi, HH Chng LUPUS: 2006; 15(12): 899-900
3. Mortality and hospitalization outcomes of interstitial lung disease and pulmonary hypertension in the Singapore systemic sclerosis cohort Noviani M, Saffari SE, Tan JL, Yip JWL, Teng GG, Law WG, Chan GYL, Santosa A, Lim AYN, Hong C, Ng SA, Tay ELW, Ruan W, Yap J, Low AHL. Semin Arthritis Rheum. 2019 Nov 13. pii: S0049-0172(19)30686-9

Board member, Chapter of Rheumatology, Academy of Medicine, Singapore.

Fellow of American College of Rheumatology.

Member of Singapore Society of Rheumatology.